Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases with unmet medical needs. It operates two segments: Specialized BioTherapeutics (HyBryte for CTCL, SGX302 for psoriasis, dusquetide for Behcet's Disease and oral mucositis) and Public Health Solutions (RiVax ricin vaccine, SGX943 for infectious disease, filovirus vaccines, CiVax for COVID-19), leveraging its proprietary ThermoVax heat stabilization platform with government funding support.
Q2 FY2026 — expected 2026-09-19
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001104659-26-037701 | EDGAR | 75K words |
| 2025-03-21 | 2024-12-31 | 0001558370-25-003459 | EDGAR | — |
| 2024-03-15 | 2023-12-31 | 0001558370-24-003402 | EDGAR | — |
| 2023-03-31 | 2022-12-31 | 0001558370-23-005304 | EDGAR | — |
| 2022-03-29 | 2021-12-31 | 0001558370-22-004605 | EDGAR | — |
| 2021-03-30 | 2020-12-31 | 0001213900-21-018698 | EDGAR | — |
| 2020-03-30 | 2019-12-31 | 0001213900-20-007959 | EDGAR | — |
| 2019-03-26 | 2018-12-31 | 0001213900-19-004865 | EDGAR | — |
| 2018-03-15 | 2017-12-31 | 0001213900-18-003007 | EDGAR | — |
| 2017-03-27 | 2016-12-31 | 0001213900-17-002845 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2025-11-07 | 2025-09-30 | 0001104659-25-108475 | EDGAR | 30K words |
| 2025-08-14 | 2025-06-30 | 0001558370-25-011554 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0001558370-25-007171 | EDGAR | — |
| 2024-11-08 | 2024-09-30 | 0001558370-24-015054 | EDGAR | — |
| 2024-08-09 | 2024-06-30 | 0001558370-24-011740 | EDGAR | — |
| 2024-05-10 | 2024-03-31 | 0001558370-24-007782 | EDGAR | — |
| 2023-11-13 | 2023-09-30 | 0001558370-23-018818 | EDGAR | — |
| 2023-08-21 | 2023-06-30 | 0001558370-23-015144 | EDGAR | — |
| 2023-05-15 | 2023-03-31 | 0001558370-23-009929 | EDGAR | — |
| 2022-11-10 | 2022-09-30 | 0001558370-22-017406 | EDGAR | — |
| 2022-08-12 | 2022-06-30 | 0001558370-22-013491 | EDGAR | — |
| 2022-05-13 | 2022-03-31 | 0001558370-22-008747 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-02-12 | 0001104659-26-014267 | EDGAR | 1K words |
| 2026-01-23 | 0001104659-26-006233 | EDGAR | — |
| 2025-11-18 | 0001104659-25-113645 | EDGAR | — |
| 2025-09-29 | 0001104659-25-094507 | EDGAR | — |
| 2025-08-18 | 0001558370-25-011625 | EDGAR | — |
| 2025-08-15 | 0001558370-25-011619 | EDGAR | — |
| 2025-07-31 | 0001104659-25-072708 | EDGAR | — |
| 2025-06-20 | 0001558370-25-008772 | EDGAR | — |
| 2025-03-28 | 0001558370-25-003987 | EDGAR | — |
| 2025-02-10 | 0001558370-25-000726 | EDGAR | — |
336 total filings indexed. 304 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0000812796 |
| Ticker | SNGX |
| Exchange | Nasdaq |
| SIC | 2834: Pharmaceutical Preparations |
| Incorporated | DE |
| Headquarters | Princeton, New Jersey |
| Website | https://www.soligenix.com |
| Listed | 1994-04-05 |
This is the free public profile. For structured JSON with full provenance chain, use the API:
JSON Profile Stock Quote AI Readiness Report